| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/15/2007 | WO2007017095A1 A process for the preparation of substituted phenyl ether compounds and rosiglitazone |
| 02/15/2007 | WO2007017067A2 Modulators of the melted protein and uses thereof |
| 02/15/2007 | WO2007016777A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | WO2007016771A1 Dosing regimen for weight loss |
| 02/15/2007 | WO2007016764A1 Composition and method for prevention and treatment of type i diabetes |
| 02/15/2007 | WO2007016757A1 Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| 02/15/2007 | WO2006125180B1 Piperazine derivatives and their uses as therapeutic agents |
| 02/15/2007 | WO2006117212A3 Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| 02/15/2007 | WO2006108599A3 Ghrelin binding nucleic acids |
| 02/15/2007 | WO2006009975A3 Histamine to treat disorders affecting muscle function |
| 02/15/2007 | US20070037996 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 02/15/2007 | US20070037995 A Substantially Cell Membrane Impermeable Compound And Use Thereof |
| 02/15/2007 | US20070037884 Novel succinate salt of O-desmethyl-venlafaxine |
| 02/15/2007 | US20070037879 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 02/15/2007 | US20070037878 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 02/15/2007 | US20070037870 Novel substance having alpha-glucosidase inhibiting activity and food containing the same |
| 02/15/2007 | US20070037864 Intermediates for the preparation of lipoxin A4 analogs |
| 02/15/2007 | US20070037859 Substituted Thiazolidinedione Derivative, Process for Its Preparation and Its Pharmaceutical Use |
| 02/15/2007 | US20070037836 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide |
| 02/15/2007 | US20070037834 Bicyclic pyrimidine derivatives |
| 02/15/2007 | US20070037826 Indolylmaleimide derivatives |
| 02/15/2007 | US20070037823 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 02/15/2007 | US20070037778 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide |
| 02/15/2007 | US20070037772 Pyrazolidinol compounds |
| 02/15/2007 | US20070037606 Transmitter of wireless microphone, receiver for wireless microphone, portable information communication device, and wireless microphone communication system |
| 02/15/2007 | US20070037147 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 02/15/2007 | US20070036872 Alpha-glucosidase activity inhibitor |
| 02/15/2007 | US20070036806 have an increased half-life, decreased immunogenicity, and reduce effector activity; diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying |
| 02/15/2007 | US20070036768 Systems and methods for treating patients with processed lipoaspirate cells |
| 02/15/2007 | CA2659961A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | CA2658678A1 Composition and method for prevention and treatment of type i diabetes |
| 02/15/2007 | CA2626723A1 Xanthine derivatives as selective hm74a agonists |
| 02/15/2007 | CA2618963A1 Xanthine derivatives as selective hm74a agonists |
| 02/15/2007 | CA2618622A1 Novel cercosporamide derivative |
| 02/15/2007 | CA2618370A1 Oxazolopyridine derivatives as sirtuin modulators |
| 02/15/2007 | CA2618368A1 Imidazopyridine derivatives as sirtuin modulating agents |
| 02/15/2007 | CA2618360A1 Benzothiazoles and thiazolopyridines as sirtuin modulators |
| 02/15/2007 | CA2618112A1 Pyridone compound |
| 02/15/2007 | CA2618069A1 Dihydroxyanthraquinones and their use |
| 02/15/2007 | CA2617969A1 Therapeutic agent for diabetes |
| 02/15/2007 | CA2617557A1 Benzimidazole derivatives as sirtuin modulators |
| 02/15/2007 | CA2617532A1 Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds |
| 02/15/2007 | CA2617327A1 Salts of vildagliptin |
| 02/15/2007 | CA2616451A1 Substituted benzyl derivatives as gsk-3 inhibitors |
| 02/15/2007 | CA2616249A1 A process for the preparation of substituted phenyl ether compounds and rosiglitazone |
| 02/15/2007 | CA2615941A1 Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| 02/14/2007 | EP1752448A2 Fluvastatin sodium crystal form lxxix, processes for preparing it, compositions containing it and methods of using it |
| 02/14/2007 | EP1752445A1 New crystalline form III of agometalin, the process for its preparation and pharmaceutical compositions containing it |
| 02/14/2007 | EP1752444A1 New crystalline form IV of agometaline, the process for making it and pharmaceutical compositions containing it |
| 02/14/2007 | EP1752443A1 New crystalline form V of agometaline, the process for its preparation and the pharmaceutical compositions containing it |
| 02/14/2007 | EP1752154A1 Composition comprising fermented tea extract as the main component and having effect of incrasing adiponectin |
| 02/14/2007 | EP1752147A1 Drug for prevention or treatment of diabetes |
| 02/14/2007 | EP1752146A1 Therapeutic agent for diabetes |
| 02/14/2007 | EP1752145A1 Therapeutic agent for hyperlipemia and therapeutic agent for diabetes |
| 02/14/2007 | EP1752144A1 Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component |
| 02/14/2007 | EP1751184A2 Fgf-21 fusion proteins |
| 02/14/2007 | EP1751126A1 Alkyl carbamate-substituted butyrolactones serving as lipase inhibitors |
| 02/14/2007 | EP1751111A1 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| 02/14/2007 | EP1751103A1 4-(5-(aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
| 02/14/2007 | EP1750745A1 Methods of inhibiting proinflammatory cytokine expression using ghrelin |
| 02/14/2007 | EP1750730A2 Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors |
| 02/14/2007 | EP1750712A2 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| 02/14/2007 | EP1750699A2 Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds |
| 02/14/2007 | EP1750695A1 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight |
| 02/14/2007 | EP1750682A2 Nutritional formulations |
| 02/14/2007 | EP1750523A1 Compositions and methods for reducing or preventing obesity |
| 02/14/2007 | EP1680128B1 Myo-inositol hexaphosphate for topical use |
| 02/14/2007 | EP1615644B1 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity |
| 02/14/2007 | EP1560828B9 Imidazoquinoline derivatives as adenosine a3 receptor ligands |
| 02/14/2007 | EP1534391B1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
| 02/14/2007 | EP1533292B1 Dibenzylamine compound and medicinal use thereof |
| 02/14/2007 | EP1507514B1 Controlled release compositions of estradiol metabolites |
| 02/14/2007 | EP1438045B1 Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake |
| 02/14/2007 | EP1417228B1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/14/2007 | EP1402886B1 Lipolysis accelerator for reducing body weight and medicinal use |
| 02/14/2007 | EP1368349B1 Xanthine derivative, production and use thereof as a medicament |
| 02/14/2007 | EP1345928B1 Pyrazole compounds useful as protein kinase inhibitors |
| 02/14/2007 | EP1343876B1 Modulators of activity of g-protein-coupled receptor kinases |
| 02/14/2007 | EP1343757B1 Indole derivatives |
| 02/14/2007 | EP1315750B1 Cyclic peptides having melanocortin-4 receptor agonist activity |
| 02/14/2007 | EP1259234B9 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 02/14/2007 | EP1242452B1 Chimeric natriuretic peptides |
| 02/14/2007 | EP1143000B1 Screening method |
| 02/14/2007 | EP1128813B1 An inhalation system |
| 02/14/2007 | EP1126836B1 Benzamide potassium channel inhibitors |
| 02/14/2007 | EP1124959B1 Cell surface molecule-induced macrophage activation |
| 02/14/2007 | EP0999845B1 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 02/14/2007 | CN1914211A Preventive or therapeutic agent for diabetic maculopathy |
| 02/14/2007 | CN1914206A 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments |
| 02/14/2007 | CN1914195A Substituted quinoline compounds |
| 02/14/2007 | CN1914189A Spiro-benzodioxoles and their use as CB1 antagonists |
| 02/14/2007 | CN1914180A Indazole derivatives as inhibitors of hormone-sensitive lipases |
| 02/14/2007 | CN1913911A Physiologically functional drinks and compositions |
| 02/14/2007 | CN1913899A Anorectic |
| 02/14/2007 | CN1911965A Binding domain-immunoglobulin fusion proteins |
| 02/14/2007 | CN1911930A Chemokine receptor anagonists, methods and use therefor |
| 02/14/2007 | CN1911925A 3,4-dihydro-III 2 benzopyran-1 ketone kind compound, its preparation method and use |
| 02/14/2007 | CN1911915A Lactam compound and medicinal use thereof |
| 02/14/2007 | CN1911913A New neuropeptide YY5 receptor antagonists |
| 02/14/2007 | CN1911448A Zinc supplements based on cation exchange resin and its preparation method and use |